Literature DB >> 1317538

Biology and molecular aspects of herpes simplex and varicella-zoster virus infections.

T J Liesegang1.   

Abstract

The herpes simplex and varicella-zoster viruses are members of the subfamily alpha herpesviruses with specific properties of the virion and with the capacity to establish latent infections in humans. The genome of each of these viruses has been determined with an estimate of the number of genes and proteins encoded. The biology and molecular events of the herpes simplex virus productive and latent infection have been detailed with the use of both in vitro and in vivo model systems. The neuron is the site of latency in the ganglia with a limited transcription of genes expressed during the latent period. The specific molecular regulation of latency and reactivation are not well established. There are co-cultivation, electron microscopy, and biochemical studies that support the concept of corneal latency, although this has not been proven conclusively. Details about the varicella-zoster virus biology and molecular events are not as well advanced since animal models have been lacking. The biology of the productive infection (varicella) is different from herpes simplex virus infection since the portal of entry is the respiratory system. Data support the concept of the maintenance of latency within satellite cells in the ganglia rather than within neurons. There are multiple genes expressed during this latency. These features may explain the different clinical presentations and course of reactivation (zoster) compared with herpes simplex virus reactivation.

Entities:  

Mesh:

Year:  1992        PMID: 1317538     DOI: 10.1016/s0161-6420(92)31921-9

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  10 in total

Review 1.  Corneal ulceration in pediatric patients: a brief overview of progress in topical treatment.

Authors:  Serina Stretton; Usha Gopinathan; Mark D P Willcox
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

2.  Recombinants are isolated at high frequency following in vivo mixed ocular infection with two avirulent herpes simplex virus type 1 strains.

Authors:  R L Kintner; R W Allan; C R Brandt
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

3.  Incidence, recurrence, and outcomes of herpes simplex virus eye disease in Olmsted County, Minnesota, 1976-2007: the effect of oral antiviral prophylaxis.

Authors:  Ryan C Young; David O Hodge; Thomas J Liesegang; Keith H Baratz
Journal:  Arch Ophthalmol       Date:  2010-09

Review 4.  Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin).

Authors:  William Stevenson; Sheng-Fu Cheng; Mohammad H Dastjerdi; Giulio Ferrari; Reza Dana
Journal:  Ocul Surf       Date:  2012-01-25       Impact factor: 5.033

5.  Ocular complications of heart, lung, and liver transplantation.

Authors:  P Ng; P McCluskey; G McCaughan; A Glanville; P MacDonald; A Keogh
Journal:  Br J Ophthalmol       Date:  1998-04       Impact factor: 4.638

6.  DNA amplification for the in vitro detection of Candida albicans in head and neck squamous cell carcinomas.

Authors:  J A Werner; T Görögh; B M Lippert; H Rudert
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

Review 7.  Ocular herpes: the pathophysiology, management and treatment of herpetic eye diseases.

Authors:  Lucy Zhu; Hua Zhu
Journal:  Virol Sin       Date:  2014-12-15       Impact factor: 4.327

8.  Concurrent reactivation of varicella zoster virus and herpes simplex virus in an immunocompetent child.

Authors:  Hyun-Ho Park; Mu-Hyoung Lee
Journal:  J Korean Med Sci       Date:  2004-08       Impact factor: 2.153

Review 9.  Adoption of Innovation in Herpes Simplex Virus Keratitis.

Authors:  James Chodosh; Lawson Ung
Journal:  Cornea       Date:  2020-11       Impact factor: 3.152

10.  Role of TH17 Responses in Increasing Herpetic Keratitis in the Eyes of Mice Infected with HSV-1.

Authors:  Satoshi Hirose; Ujjaldeep Jaggi; Shaohui Wang; Kati Tormanen; Yoshiko Nagaoka; Makoto Katsumata; Homayon Ghiasi
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-06-03       Impact factor: 4.799

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.